Abstract Residual platelet reactivity (RPR) following coronary artery bypass grafting (CABG) might be related to thrombotic complications and major ischemic cardiac events. The aim of this study was to evaluate the changes in platelet reactivity monitored pre-and postoperatively using multiple-electrode aggregometry (MEA) and to propose an alternative therapeutic approach in a subgroup of patients with postoperative RPR. Ninety-nine patients undergoing elective CABG were enrolled in the study, of whom 41 (41.4%) were diabetic. Preoperatively, all patients received 100 mg acetylsalicylic acid (ASA), with 47 of 99 (47.4%) patients receiving an additional 75 mg clopidogrel (CLO). The blood samples were drawn the day before surgery, and on the first and 4th postoperative day. Platelet count and fibrinogen level were documented, as well as type and daily dose of antiplatelet therapy (APT) received pre-and postoperatively. Multiple-electrode aggregometry using tests based on arachidonic acid (ASPI test) and adenosine diphosphate (ADP test) was performed on the day before and 4 days after surgery. Preoperatively, we detected 31 of 99 (31.3%) patients with RPR (ASPI [ 30 AUC). Platelet count correlated with both the ASPI (P = 0.03) and ADP (0.002) tests. Fibrinogen correlated with ADP test values (P \ 0.001) and was found to have a higher level in the diabetic subgroup (P = 0.01). In comparison with preoperative results, we detected higher values of ASPI test postoperatively (P = 0.04), with 46 of 99 (46.5%) patients having RPR despite a higher dose of 300 mg ASA being administered. Postoperatively, diabetic patients had higher ASPI test values (P = 0.01), and a higher proportion of patients with RPR compared with the nondiabetic subgroup (58.5 vs 38%, P = 0.04). The subgroup of patients with detected ASPI [30 AUC at the 4th postoperative day consequently received as a part of our clinical routine an additional 75 mg CLO per day, in terms of platelet inhibition optimization. Multiple-electrode aggregometry can recognize patients with RPR during both the pre-and post-CABG period. Postoperatively administered ASA (300 mg) did not sufficiently inhibit platelet aggregation in 46.5% of post-CABG patients. In this group of patients a switch to dual APT should be considered.
Introduction
The outcome of coronary artery bypass grafting surgery (CABG) depends mainly on the patency of the graft vessels. Graft patency is mainly influenced by the type of the graft used, but also by diameter and degree of atherosclerotic changes of the distal vessel into which the graft is placed. Aortocoronary vein graft disease is composed of three distinct but interrelated pathological processes: thrombosis, intimal hyperplasia, and atherosclerosis [1] . Early thrombosis is a major cause of vein graft attrition during the first month after CABG. Bypass patency can be improved with antiplatelet therapy (APT), which is the mainstay of treatment for patients after CABG. Acetylsalicylic acid (ASA) is the best studied, most used, and least toxic of the platelet inhibitors [2, 3] . A beneficial effect of ASA on vein graft patency has been shown during the first year after CABG [4] [5] [6] . However, some patients experience adverse cardiac events despite treatment with APT. Some of such events may be caused by residual platelet reactivity (RPR) after APT administration, which inevitably suggests the need for an increase in antiplatelet drug dose, or administration of another antiplatelet agent as a supplement. Residual platelet reactivity after ASA or clopidogrel (CLO) administration, as assessed by platelet function tests, varies widely among patients, and has been reported to range from 1% to 45% for the two drugs [7] . Residual platelet reactivity following CABG might be related to thrombotic complications and major ischemic cardiac events. This phenomenon has already been described in the literature [8, 9] . Residual platelet reactivity can postoperatively present as a nonreactive state of platelets to APT. Recently, a new point-of-care assay for rapid and standardized assessment of platelet function parameters, named multiple-electrode aggregometry (MEA), using a device called a multiplate analyzer (Dynabyte, Munich, Germany), has become available at our department. The aim of this study was to evaluate the RPR using MEA, both pre-and postoperatively, in patients following CABG, and to propose the alternative therapeutic approach to patients with observed postoperative RPR to the Aspirin-Sensitive Patients Identification (ASPI) test. Antiplatelet therapy in diabetes, however, is still a matter of intense debate due to a high prevalence of RPR, described elsewhere [10] . An additional aim of our study was to clarify whether diabetic patients following CABG showed a higher rate of RPR after ASA administration.
Patients and methods

Patient selection
The study was conducted in a prospective observational mode. After Institutional Review Board approval and written informed consent, 99 adult men and women scheduled for elective CABG requiring cardiopulmonary bypass (CPB) between August 2009 and March 2010 were prospectively studied. Criteria for excluding patients from the group of subjects were: missing consent, patients with cardiac surgical procedures other than isolated CABG, on APT other than ASA or CLO, patients with inaccurate APT administration documentation or missing data, urgent surgery, off-pump CABG, and redo CABG. In our study cohort APT was administered by the referral cardiologist. All patients were admitted to our department with a daily dose of 100 mg ASA, which was continued up to the day of surgery. Forty-seven (47.4%) patients received a daily dose of 75 mg CLO in addition to ASA, and CLO was excluded at our department prior to surgery with individually different time intervals from CLO cessation to surgery, from 2 to 8 days, respectively. Time from CLO cessation to surgery varied individually, based on the date of admission to our department and the date of the procedure. Patients received APT continuously for at least 10 days prior to admission to our department.
Perioperative management
All patients had the same anesthetic and perfusion teams, and were admitted at least 1 day before surgery. Surgery was performed in a single unit with standard surgical techniques. Anesthesiologists and surgeons were blinded to the preoperative results of the MEA measurements.
The patients received diazepam and morphine 30 min prior to the induction of anesthesia. Endotracheal tube, urinary catheter, as well as radial artery and pulmonary artery catheters were inserted. The anesthetic regime included induction and maintenance of anesthesia with midazolam, fentanyl, and pancuronium bromide; this was coupled with sevoflurane inhalation. The initial ventilator settings included a tidal volume of 8 ml/kg, and a respiratory rate of 12 breaths/min. Typically the FiO 2 was set at 50%. The cardiopulmonary circuit consisted of the Medtronic Affinity Trillium membrane oxygenator, venous reservoir, and PVC tubing (Medtronic, Minneapolis, MN, USA) and a Stoeckert III roller pump (Stoeckert, Munich, Germany). It was established via central cannulation, targeting flow at 2.2 L/min per m 2 and mean blood pressure of 60 mmHg. The heart was arrested with cold blood cardioplegia. Systemic heparinization aiming at an activated clotting time [480 s was used, followed by full reversal with protamine after decannulation. A dose of 1 g tranexamic acid was given at the induction of anesthesia and after protamine administration. Inotropic support was initiated in order to maintain a cardiac index greater than 2.2 L/min per m 2 . Arterial and venous grafts were used for bypass diseased coronary vessels. The lungs were open to atmosphere during CPB. Weaning from CPB was initiated once the patient's rhythm had stabilized and normothermia had been achieved. Packed red blood cells were added during CPB if the hematocrit level was\20%. Volume replacement in the intensive care unit was administered as deemed necessary by the attending physician using hydroxyethyl starch 6% 130/0.4 and lactated Ringer's solution. Packed red blood cells were transfused if deemed necessary by the consultant anesthesiologist.
Blood sampling
Blood samples for MEA measurements were obtained on the day before surgery and on the 4th postoperative day using venipuncture, and blood was collected in 4 ml heparin (Lithium Heparin 68 IU) coated BD Vacutainer plastic tubes. Routine laboratory tests were performed each day from the day before surgery to the 4th postoperative day. The same person, not directly involved in patient care, performed all measurements. Blood samples were at rest for 30 min after blood withdrawal and MEA was performed subsequently.
Multiple-electrode aggregometry
Whole blood aggregation was determined using a newgeneration impedance aggregometer (Multiplate analyzer; Dynabyte Medical, Munich, Germany). A detailed description of the method has already been published [11] . In brief, MEA is based on the principle that blood platelets are nonthrombogenic in their resting state but expose receptors on their surface when they get activated, which allows them to attach onto vascular injuries and artificial surfaces. When platelets stick on the Multiplate sensor wires, they enhance the electrical resistance between them, which is continuously recorded. An increase in impedance is expressed in arbitrary area under the curve (AUC) units, highlighted as the parameter with the highest diagnostic power [11, 12] . The analysis itself needs 3 min for incubation and 6 min for the measurement after stimulation. Platelet aggregation was determined in response to stimulation with arachidonic acid with a final concentration of 0.5 mM (ASPI test designed to evaluate the effect of ASA) and adenosine diphosphate (ADP) with a final concentration of 6.4 lM (ADP test designed to evaluate the effect of thienopyridines, such as CLO). The RPR to ASPI aggregation test was defined by an AUC of[30 U (75th percentile of aggregation in ASPI test from 65 control patients with coronary artery disease on chronic 100-mg ASA daily treatment, scheduled for CABG) [13] . This definition is in concordance with literature sources published by our institutional colleagues with the same setting used in a cohort of 110 patients with stable coronary artery disease receiving a daily dose of 100 mg ASA [14] . Similar results, although with a different anticoagulant used for blood sampling for MEA, were also described [15, 16] .
Statistical analysis
For statistical analysis we used MedCalc for Windows software (MedCalc Software, Mariakerke, Belgium). The Kolmogorov-Smirnov test was used for evaluating normality of distribution of all continuous variables. An independent t test was used for comparison of two study groups. The chi-squared test was used for data comparison between groups. A value of P B 0.05 was considered statistically significant.
Results
Patients
All patients from the sample were discharged from hospital. The cohort group was divided into two subgroups regarding preoperative APT. We observed RPR both preand postoperatively. No difference occurred among the study groups concerning age, sex, and weight. Perioperative laboratory values (hemoglobin, hematocrit, platelet count, and fibrinogen level) did not differ among the patients. Descriptive statistics of two groups is presented in Tables 1 and 2. Platelet count, fibrinogen level, platelet aggregation assessment, and RPR prevalence Considering all 99 CABG patients, we observed 31 (31.3%) patients with RPR (ASPI [30 AUC) preoperatively, with no significant difference among the groups regarding APT administered preoperatively (Table 3) . Following the routine clinical protocol, all patients received 300 mg ASA postoperatively, starting at the first postoperative day. On the 4th postoperative day we registered 46 of 99 (46.5%) CABG patients with RPR despite a higher dose of APT, suggesting platelet hyperactivity. A postoperatively registered increase of 15.2% in the proportion of patients with RPR was found to be significant, P = 0.04. In the group of patients with preoperative registered RPR (n = 31), we found a proportion of 18 of 31 patients (58.1%) with RPR after surgery, while in the group with preoperatively adequate platelet inhibition (n = 68) we registered a proportion of 28 of 68 patients (41.1%) with RPR postoperatively. A greater number of patients with preoperative RPR were found to have RPR in the postoperative period, but the difference did not reach statistical significance.
Postoperatively, we detected higher values of both the ASPI test (P = 0.04, shown in Fig. 1 ) and ADP test (P = 0.002, shown in Fig. 2 ) in comparison with preoperative results.
In addition to the aforementioned results that suggest a postoperative RPR proportional increase, we found a significant (P \ 0.001) perioperative increase in fibrinogen level (Fig. 3) .
Platelet count and fibrinogen were correlated with ASPI and ADP tests both pre-and postoperatively.
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Preoperatively, we detected a significant correlation between platelet count and both ASPI (P = 0.03) and ADP tests (P = 0.002). Fibrinogen correlated significantly with ADP test values (P\0.001). On the 4th postoperative day, only platelet count and ADP test correlated significantly (P = 0.01).
Residual platelet reactivity and diabetes mellitus
We analyzed the difference in the degree of platelet inhibition among patients with respect to the presence of diabetes as a comorbidity, both pre-and postoperatively ( 
Residual platelet reactivity and gender
We assessed RPR prevalence with respect to gender both pre-and postoperatively. In the female group, preoperative assessment revealed 11 of 25 (44%) patients with RPR. In the male group, 20 of 74 (27%) patients showed RPR at the same time. Postoperatively, RPR occurred in 12 of 25 (48%) female patients, and in 34 of 74 (45.9%) male patients. Although the differences in RPR prevalence with respect to gender were not significant both pre-and postoperatively, it is worth mentioning that the male population Of note, we observed a nonsignificant difference in the prevalence of diabetes mellitus among genders.
Discussion
Our study presumably identified a group of patients with RPR to the ASPI aggregation test and sensitive to the effect of ASA, both pre-and postoperatively. Platelet aggregation, assessed with the MEA ASPI test, was not sufficiently inhibited in 46.5% post-CABG patients despite 300 mg ASA administered postoperatively. The proportion of patients with RPR was higher postoperatively, despite a higher daily dose of 300 mg ASA (P = 0.04).
Coronary artery disease is a leading cause of death in developing and developed countries [2, 17] . No uniform guidelines exist for the postoperative prevention of thrombotic complications after CABG [18] . It is widely accepted that platelets play a pivotal role in the development of thrombosis [19, 20] . Early graft failure is hypothesized to be related to thrombus development, of which RPR may be an important component [21] .
Several laboratory assays are commonly used to assess response to APT. The fact that aggregation in MEA takes place on surfaces is a major difference compared with other methods such as Born aggregometry and single platelet counting. Multiple-electrode aggregometry uses anticoagulated whole blood for analysis. Whole blood is the physiological environment where platelet function takes place in vivo, and the use of whole blood for in vitro testing eliminates the need for time-consuming centrifugation steps required for Born aggregation measurements. The ideal anticoagulant for accurate platelet aggregometry remains controversial. Citrate is still used as the anticoagulant of choice for platelet testing. At our department only citrate and heparin are available as blood-sample anticoagulants. Heparin may be used as an anticoagulant for platelet aggregation studies [22, 23] , although early literature refers to heparin affecting aggregation results [24] . Therefore, a different reference interval of test values should be considered. We obtained blood samples by performing anticoagulation with heparin. Truss et al. [22] has compared aggregation data obtained by performing MEA using either citrate or heparin as an anticoagulant. Multiple-electrode aggregometry responses to arachidonic acid, ADP, and collagen, obtained with heparin as anticoagulant, resulted in lower values than data obtained with citrated blood. Taking into consideration the fact that we regularly use unfractionated heparin as an anticoagulant for MEA, we devised our own definition of RPR. The RPR to ASPI aggregation test was defined by an AUC of [30 U (75th percentile of aggregation in ASPI test from 65 control patients with coronary artery disease on chronic 100-mg ASA daily treatment, scheduled for CABG) [13] .
Antiplatelet therapy management
Based on our data supporting that patients after CABG have hyperactive platelets, the use of low molecular weight heparin as additional thromboprophylaxis may not be the optimal strategy, because low molecular weight heparin does not inhibit platelet function per se. At present, there is no established therapeutic approach for managing low response to ASA that has been shown in large trials to have clinical benefit. Our data presumably identified a subgroup of patients with RPR following CABG who may be at increased risk for developing thromboembolic complications. In this subgroup of patients, higher doses of ASA would not be prudent in terms of worsening endothelial-mediated arterial dilatation [25] . These patients could benefit from a more aggressive antithrombotic treatment regimen such as dual APT with CLO addition to ASA therapy. Clopidogrel is very useful, especially taking into consideration the fact that our study cohort had higher postoperative ADP aggregation test values (P = 0.002), which can be specifically inhibited by CLO. However, this therapeutic approach needs a randomized controlled trial with a large study group to evaluate the benefit of such treatment. The benefit of such a treatment regimen has been investigated in the CASCADE trial [26] . This trial investigated the impact of dual APT on venous graft disease in CABG patients. The primary outcome was saphenous vein graft intimal hyperplasia, determined by intravascular ultrasound. Secondary outcomes were graft patency, major adverse cardiovascular events, and major bleeding. No significant difference occurred regarding both the primary and secondary outcomes between the ASA-CLO and ASA-placebo postoperative APT regimen group. The lack of objective quantification of the antiplatelet effect of both ASA and CLO constitutes a major drawback of the study [27] . Nevertheless, since RPR raises the incidence of adverse cardiovascular events and venous graft occlusions, it would seem critical to adjust for this variable [1] . This problem was further amplified by ignoring the variability to CLO response. Therefore, randomization of patients with MEA-assessed inappropriate response to ASA on addition of CLO or placebo could reveal different results. Further, MEA evaluation of response to CLO in a group receiving dual APT could be useful. Another alternative therapeutic approach is mono-APT with CLO. The Aspirin Non-Responsiveness and Clopidogrel End point Trial (ASCET) is currently evaluating whether switching to CLO will be superior to continuing ASA therapy in improving clinical outcomes in low responders to ASA [28] . Our study showed that diabetics are prone to have RPR after ASA administration, especially after CABG. Increased baseline platelet reactivity may be more commonly observed in specific clinical scenarios such as diabetes mellitus, as described in the literature [10] . Antiplatelet therapy in diabetes is still a major issue, due to a high prevalence of RPR after APT administration [10] . The higher prevalence of RPR described in our diabetic subgroup might be a major contributor to poorer outcomes among diabetic patients. It has been recently reported that platelet reactivity is tightly associated with glycemic control in diabetics [29] . Elevated glycosylated hemoglobin levels are common among diabetic patients scheduled for coronary surgery, particularly in patients receiving insulin, and are associated with more frequent occurrence of perioperative myocardial infarction [30] . These data suggest that diabetic patients with poor metabolic control and the high degree of platelet reactivity may benefit from aggressive APT strategies [31] . Using MEA to guide APT allowed us to tailor therapy individually after MEA assessment at the 4th postoperative day. An individually tailored therapeutic approach significantly improves clinical outcomes. Awidi et al. [2] found that the combination of ASA and CLO had greater inhibitory effects on platelet function than either agent alone. However, we found no significant difference in the proportion of low responders to ASA between groups with respect to preoperative APT regime strategy. The reason for such a difference might be that patients undergoing CABG are those who may be considered ''treatment failures'' following percutaneous coronary interventions, as described by Preisman et al. [32] . Prospective, randomized trials evaluating outcomes, with platelet function assessment, are needed to clarify the benefits of dual APT.
Using thromboelastography for assessment of platelet function, Bochsen et al. [8] suggested that CABG patients are prone to platelet hyperactivity at the 4th postoperative day. Although revealed with a different assay, the study described the same phenomenon as described herein. Using modified thromboelastography with arachidonic acid as platelet agonist, Preisman et al. [32] showed a rate of 44% of nonresponsiveness to ASA. Using the turbidimetric method for platelet aggregation measurement, Kempfert et al. [33] reported 28.8% patients with RPR before CABG. Postoperatively almost half of the patients (49%) developed RPR. These results are similar to the results of our study, although it is worth mentioning that the patients had different postoperative ASA dosing regimens to the patients in our study. A standard definition to assess antiplatelet drug response has not been fully established and differences in assays, agonist concentrations, and cutoff values have contributed to the existing variability [7] . Antiplatelet response to ASA, as assessed by platelet function tests, varies widely among patients, which could possibly explain early graft occlusion within the first month after surgery despite appropriate ASA treatment [4] . These results suggest that a more aggressive antithrombotic treatment might be warranted for patients undergoing CABG in the postoperative period.
Limitations of study
We have not performed an in-house reference interval of normal values of platelet aggregation assessed by MEA with arachidonic acid and ADP as agonists by using heparin as anticoagulant. In addition, in-house studies of imprecision of the method have not been performed. Hemostatic studies are usually performed on citrated blood samples. Due to the fact that heparin was used as anticoagulant in our study, different from those of other authors, we obtained a cutoff value for RPR by using the same setting in the 65 consecutive patients requiring CABG.
The study was conducted as being prospective and observational, and we did not analyze the outcome with respect to MEA results and subsequent APT adjustment. The purpose of the study was to evaluate RPR prevalence both pre-and postoperatively, with the APT adjustment proposal on RPR appearance. Our study contained no randomization, and the scope of this study did not include identification of the event rate of thromboembolic complications with regard to MEA results.
The impact of dual APT on the reduction of cardiovascular ischemic events was not evaluated. We did not repeat MEA measurements after APT adjustment and so did not distinguish whether the RPR was permanent or temporary. Although we assessed the ADP test both preand postoperatively, preoperatively we did not assess RPR to ADP test with respect to CLO administration. The reason lies in the fact that measurements were performed on the day before surgery, and CLO was excluded from therapy at different time intervals from measurements, so technically it would be impossible to identify someone as CLO resistant, i.e., 5 days after CLO withdrawal.
However, the use of the MEA ADP test, sensitive to the effect of CLO, was useful because it showed a significant increase (P = 0.002) in values in the postoperative period, which inevitably suggests the use of CLO in patients with RPR to ASPI test detected postoperatively.
